{"id":"NCT03706079","sponsor":"AstraZeneca","briefTitle":"Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma","officialTitle":"A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (DESTINATION)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-07","primaryCompletion":"2021-10-26","completion":"2022-05-18","firstPosted":"2018-10-15","resultsPosted":"2023-02-09","lastUpdate":"2023-06-06"},"enrollment":951,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Tezepelumab","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tezepelumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Subjects who completed either D5180C00007 or D5180C00009 will be offered the opportunity to consent for the Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma. The study consists of a treatment phase, followed by a follow-up phase where subjects will not receive IP. The length of the follow up phase is determined by which study the subject had previously completed.","primaryOutcome":{"measure":"Exposure Adjusted Incidence Rates of AEs/SAEs","timeFrame":"Baseline (Week 0 in predecessor study) to Week 104. For subjects switching treatments from placebo in the predecessor to tezepelumab in DESTINATION, all data collected after first dose of tezepelumab are excluded.","effectByArm":[{"arm":"NAVIGATOR Rand Teze","deltaMin":49.62,"sd":null},{"arm":"NAVIGATOR Rand Pbo","deltaMin":62.66,"sd":null},{"arm":"SOURCE Rand Teze","deltaMin":47.15,"sd":null},{"arm":"SOURCE Rand Pbo","deltaMin":69.97,"sd":null}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":180,"countries":["United States","Argentina","Australia","Austria","Brazil","Canada","France","Germany","Israel","Poland","Russia","Saudi Arabia","South Africa","South Korea","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","Vietnam"]},"refs":{"pmids":["39326921","38697286","36702146","33087119"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00018&amp;attachmentIdentifier=8a2b972e-4a6e-43c5-af7a-ae92fb0c49f3&amp;fileName=d5180c00018-sap-ed-3-redact.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00018&amp;attachmentIdentifier=50cb4a27-8cdd-456e-8557-fdeccbd69d40&amp;fileName=d5180c00018-csp-v6-redact.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00018&amp;attachmentIdentifier=d7be4478-ea53-4972-9b54-6771c586611a&amp;fileName=d5180c00018-study-synopsis-redact.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":82,"n":528},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Headache","Sinusitis","Bronchitis"]}}